Pfizer’s Revenue by Segment (2016-2021)

Download

About

This statistic highlights Pfizer’s Revenue by Segment from 2016 onwards, split between Biopharma, Essential Health, Innovative Health, and Upjohn.
Subscribe to Pro or Enterprise plans to unlock this feature.
More information
Subscribe to Pro or Enterprise plans to unlock this feature.
Contact the Analyst
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on reddit
Share on facebook
Share on twitter
Share on linkedin
Share on email

Become a smarter investor today.

Access Business Quant for as low as $19/month

Become a smarter investor today.

Access KPI Data on listed stocks for just $19/month

This statistic highlights Pfizer’s Revenue by Segment from 2016 onwards, split between Biopharma, Essential Health, Innovative Health, and Upjohn.

Pfizer’s Revenue by Segment

Pfizer is now operating with a single segment since Q4 2020. This segment is engaged in research, innovation, development, manufacturing, marketing, sales, and distribution of biopharmaceutical products around the globe. Distribution, selling, and marketing of Pfizer’s products are done by regional commercial organizations.

Segment Revenue in Q1 2019 Revenue in Q1 2020 YOY Growth in Q1 2020 Revenue Share in Q1 2020
Biopharma $9.19 $10.01 8.95% 83.19%

(All figures in billion, except percentages)

Pfizer has a massive market capitalization of $0.2 trillion. Its 1-year revenue growth is 16.6%, while the industry average is at 12.2%. Pfizer’s 3-year revenue growth is – 5.5% which is a poor sign of fundamentals.

In December 2018, GSK’s consumer healthcare business obtained Consumer Healthcare for the formation of a consumer healthcare Joint Venture where Pfizer holds a 32% equity stake.

Biopharma

  • Array BioPharma was founded in 1998 by Dr. Tony Piscopio, Dr. Kevin Koch, Dr. David Snitman, and Dr. K.C. Nicolaou.
  • Pfizer acquired Array BioPharma Inc. in June 2019. It especially focuses on oncology meditation.
  • Biopharma is an innovative medicines business that includes six business units – Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines, and Internal Medicine.
  • Biopharma strengthens Pfizer’s oncology category. Pfizer expects a long-term growth trajectory through biopharma’s new medicines.
  • Biopharma’s revenue increased from $9.19 billion in Q1 2019 to $10.01 billion in Q1 2020 reflecting 8.95% year-over-year growth. Biopharma’s sales contributed 81.19% towards Pfizer’s top line in Q1 2020.

Essential Health 

  • Pfizer Essential Health included legacy brands that have already lost or about to lose their market in developing and emerging markets.
  • Essential Health also had an R&D organization and contract manufacturing business.
  • Some of the leading brands included in Essential health were Lyrica, Celebrex, Viagra, Lipitor, and Norvasc.
  • Essential Health generated a revenue of $5.08 million in Q1 2018. However, its operations were discontinued after Q4 2018.

Innovative Health

  • Pfizer’s innovative health focused on developing medicines, vaccines, and consumer healthcare products.
  • Pfizer’s Innovative Health included 6 business groups – Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Diseases, and Vaccines.
  • Some of the leading brands included in Innovative Health were Lyrica, Enbrel, Ibrance, and Xtandi.
  • Pfizer Innovative Health’s revenue increased from $7.42 billion in Q1 2017 to $7.83 billion in Q1 2018, reflecting a 5.58% increase.
  • Even Innovative Health’s operations were discontinued after Q4 2018 like Essential Health.

Upjohn

  • Upjohn was a pharmaceutical manufacturing firm, founded by Dr. William Upohn in 1886. Upjohn merged with Pharmacia AB formed Pharmacia and Upjohn in 1995. Pfizer owned Upjohn from 2015 until 2020.
  • Upjohn was an off-patent branded and generic established medicines business.
  •  Upjohn generated revenue of $2.02 billion in Q1 2020, marking a 34.24% year-over-year decrease. Upjohn’s sales accounted for 16.81% of Pfizer’s overall revenue in Q1 2020.
  • On 16th November 2020, Pfizer merged Upjohn with Mylan and formed Viatris through a Reverse Morris Trust structure. Thus, in Q4 2020, the financial results of Upjohn were not reflected as its operations were discontinued.

Covid-19 Vaccine

Pfizer partnered with BioNTech in March 2019, to develop the Covid-19 mRNA vaccine. Pfizer invested around $2 billion in developing this product. The vaccines were ready for the testing phase in May 2020, with four different variations. On 9th November 2020, Pfizer’s vaccine was tested on 43,500 people and the vaccine came out to be 90% effective. However, efficacy was updated to 95% in the next week. As of May 2021, Pfizer and BioNTech manufacture a minimum of 430 million doses distributing to 91 different countries and territories.

Company Overview 

Pfizer Inc. is a research-based multinational pharmaceutical and biotechnology corporation founded in 1849 by Charles Pfizer and Charles Erhart. The company is headquartered in Manhattan, New York City. Pfizer started its journey by producing antiparasitic and santonin. Further, in the 1880s Pfizer’s production of citric acid bring them a huge success.  As of 1906, Pfizer’s sales exceeded $3 million. As a result of World War 1, there was a shortage of calcium citrate, a major component for citric acid production. However, the company came across an alternative for the production of citric acid and expertise in fermentation technology. In addition, these skills were used for the mass production of Penicillin during world war 2. Penicillin was used to treat injured soldiers.

The company was incorporated in Delaware in June 1942. Pfizer’s major revenue comes from the manufacturing and selling of biopharmaceutical products. On the other hand, Pfizer also generates revenue through alliance agreements. Pfizer is famous for its medicines and vaccines. Pfizer introduced a new logo on 5th January 2021.

Did you like Pfizer’s Revenue by Segment statistic?

Access thousands of more such key performance indicator data points, on listed companies, with Business Quant.

You can also get started for free.

Read more

Our Plans

Always know what you’ll pay. No hidden costs or surprises.

  • Annual
  • Monthly

Basic

Get to know us

  • Access basic data
  • No credit card required
$0
per month
Start for Free

Investor

The essentials toolkit

  • Financial data & tools Features include : Stock screener, stock comparison, sector data, investor warnings, advanced charting tools, financial statements dating back 10+ years, stock reports, SEC filings and stock ratings. There are 200+ financial items and ratios on thousands of US stocks.
  • Download data Download underlying data in csv and xlsx (Excel) formats for offline analysis.
  • Priority support Fanatical 24*7 customer support to ensure seamless access for you.
$19
$9.9
per month*
Buy Now

51% discount until July 31

Pro

For serious investing

  • All of Investor plan All the features in Investor plan, are included in the Pro plan.
  • Granular data & tools Over 100,000 company-specific key performance indicator statistics. Examples include AT&T's broadband subscriber trends, Tesla's deliveries by model and more. Also, access financials by segment / region / product category etc.
  • Industry data & tools Access data on 40+ industries. For example, datasets include market share, smartphone shipments by vendor, subscribers by wireless carrier, historical gold production. There are 20,000+ such statistics.
$39
$19
per month*
Buy Now

Enterprise

For tailored workflows

  • All of Pro plan Get unfettered access to all our dashboards and dossiers.
  • Custom Dashboards Get tailored dashboards built specially for you, to simplify your research workflow.
  • Bespoke Research We'll expand our granular coverage to companies and sectors of your choice.
$99
per month, onwards*
Contact Us

* Billed annually, local taxes extra. 

Basic

Get to know us

  • Access basic data
  • No credit card required
$0
per month
Start for Free

Investor

The essentials toolkit

  • Financial data & tools Features include : Stock screener, stock comparison, sector data, investor warnings, advanced charting tools, financial statements dating back 10+ years, stock reports, SEC filings and stock ratings. There are 200+ financial items and ratios on thousands of US stocks.
  • Download data Download underlying data in csv and xlsx (Excel) formats for offline analysis.
  • Priority support Fanatical 24*7 customer support to ensure seamless access for you.
$19
per month*
Buy Now

51% discount on Annual plan

Pro

For serious investing

  • All of Investor plan All the features in Investor plan, are included in the Pro plan.
  • Granular data & tools Over 100,000 company-specific key performance indicator statistics. Examples include AT&T's broadband subscriber trends, Tesla's deliveries by model and more. Also, access financials by segment / region / product category etc.
  • Industry data & tools Access data on 40+ industries. For example, datasets include market share, smartphone shipments by vendor, subscribers by wireless carrier, historical gold production. There are 20,000+ such statistics.
$39
per month*
Buy Now

Enterprise

For tailored workflows

  • All of Pro plan Get unfettered access to all our dashboards and dossiers.
  • Custom Dashboards Get tailored dashboards built specially for you, to simplify your research workflow.
  • Bespoke Research We'll expand our granular coverage to companies and sectors of your choice.
$99
per month, onwards*
Contact Us

* Local taxes extra. 

BQ Star 51% off

Get Pro for 51% off

  • Access all features immediately
  • Datasets updated every day
  • Export data in CSV and XLSX formats

Offer Ends In

Starting from $39 $10 / month

.